InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.083 0.001 (1.22%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 Noxopharm 2022 Annual Report 26 Sep 2022 8:56AM $0.205 $0.083 fallen by 59.51%
$26 Final Director's Interest Notice - GK 20 Sep 2022 6:12PM $0.225 $0.083 fallen by 63.11%
$26 Resignation of Dr Graham Kelly as Non-Executive Director 19 Sep 2022 1:53PM $0.235 $0.083 fallen by 64.68%
$26 Novel Dual-cell Therapy Results in Pancreatic Cancer 14 Sep 2022 8:09AM $0.300 $0.083 fallen by 72.33%
$26 Response to ASX Price Query (Correction to ASX Ticker) 2 Sep 2022 9:51AM $0.295 $0.083 fallen by 71.86%
$26 Response to ASX Price Query 2 Sep 2022 8:26AM $0.295 $0.083 fallen by 71.86%
$26 Appendix 4E and Audited Financial Statements 25 Aug 2022 4:32PM $0.230 $0.083 fallen by 63.91%
$26 Appendix 4G and Corporate Governance Statement 25 Aug 2022 4:26PM $0.230 $0.083 fallen by 63.91%
$26 Noxopharm & UNSW Pancreatic Cancer Research at US Conference 16 Aug 2022 8:17AM $0.245 $0.083 fallen by 66.12%
$26 CEP-2 Trial Passes Safety Milestone 9 Aug 2022 8:50AM $0.235 $0.083 fallen by 64.68%
$26 DARRT-2 Trial Safety Milestone and European Site Activated 2 Aug 2022 8:20AM $0.240 $0.083 fallen by 65.42%
$26 June 2022 Quarterly Activities Report and Appendix 4C 27 Jul 2022 9:30AM $0.250 $0.083 fallen by 66.80%
$26 Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial 5 Jul 2022 8:42AM $0.215 $0.083 fallen by 61.40%
$26 $1.45M Grant to Hudson Institute for Noxopharm Collaboration 22 Jun 2022 9:33AM $0.200 $0.083 fallen by 58.50%
$26 HIMR Collaboration Secures mRNA Vic Acceleration Fund Grant 14 Jun 2022 11:11AM $0.220 $0.083 fallen by 62.27%
$26 Noxopharm Corporate Presentation 7 Jun 2022 8:44AM $0.285 $0.083 fallen by 70.88%
$26 Veyonda Abstract Published at ASCO Annual Meeting 2022 27 May 2022 8:22AM $0.230 $0.083 fallen by 63.91%
$26 March 2022 Quarterly Activities Report and Appendix 4C 28 Apr 2022 8:23AM $0.325 $0.083 fallen by 74.46%
$26 Orphan Drug Designation Granted to Noxopharm by US FDA 22 Mar 2022 8:38AM $0.320 $0.083 fallen by 74.06%
$26 First Patient Treated in CEP-2 Sarcoma Trial 28 Feb 2022 8:43AM $0.360 $0.083 fallen by 76.94%
$26 Appendix 4D and Half Year 2022 Financial Report 21 Feb 2022 4:08PM $0.380 $0.083 fallen by 78.16%
$26 Initial Director's Interest Notice - GM 1 Feb 2022 8:25AM $0.425 $0.083 fallen by 80.47%
$26 December 2021 Quarterly Activities Report and Appendix 4C 27 Jan 2022 8:52AM $0.350 $0.083 fallen by 76.29%
$26 Noxopharm Presents at H.C. Wainwright BioConnect Conference 10 Jan 2022 9:40AM $0.425 $0.083 fallen by 80.47%
$26 Noxopharm Receives A$5.865M R & D Tax Rebate 7 Jan 2022 9:16AM $0.400 $0.083 fallen by 79.25%

176 - 200 of 794 results

Page 8 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.